Melis Kabaalioglu Guner

Dr. Melis Kabaalioglu Guner

Mayo Clinic, Rochester, Indiana, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
WSWhitney leigh Stuard
Whitney leigh Stuard
MGMelis Kabaalioglu Guner
Melis Kabaalioglu Guner
Danielle M RobertsonDanielle M Robertson
Danielle M Robertson
In the eye, hyperosmolarity of the precorneal tear film triggers inflammation and the development of dry eye disease (DED), a highly prevalent condition that causes depression and disability in severe forms. A member of the insulin-like growth factor (IGF) family, the IGF binding protein-3 (IGFBP-3), is a pleiotropic protein with known roles in growth downregulation and survival. IGFBP-3 exerts these effects by blocking IGF-1 activation of the type 1 IGF-receptor (IGF-1R). Here, we examined a new IGF-independent role for IGFBP-3 in the regulation of mitochondrial and metabolic activity in ocular surface epithelial cells subject to hyperosmolar stress and in a mouse model of DED. We found that hyperosmolar stress decreased IGFBP-3 expression in vitro and in vivo. Treatment with exogenous IGFBP-3 induced an early, transient shift in IGF-1R to mitochondria, followed by IGFBP-3 nuclear accumulation. IGFBP-3 nuclear accumulation increased protein translation, blocked the hyperosmolar-mediated decrease in oxidative phosphorylation through the induction of mitochondrial hyperfusion, and restored corneal health in vivo. These data indicate that IGFBP-3 acts a stress response protein in ocular surface epithelia subject to hyperosmolar stress. These findings may lead to the development of first-in-class therapeutics to treat eye diseases with underlying mitochondrial dysfunction.

20 December 2022 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
MGMelis Kabaalioglu Guner
Melis Kabaalioglu Guner
MGMehmet Eren Guner
Mehmet Eren Guner
MOMerih Oray
Merih Oray
ITIlknur Tugal-Tutkun
Ilknur Tugal-Tutkun
To investigate the correlation between widefield fundus fluorescein angiography (WF-FA) and anterior chamber laser flare photometry (LFP-flare) in Behçet uveitis (BU). Patients with BU who underwent Heidelberg WF-FA between March 2016 and March 2018 were included. Demographics, ocular findings, LFP-flare, central macular thickness were retrospectively analyzed. Eighty-six patients (162 eyes) were included. There was a high correlation between WF-FA leakage score and LFP-flare (rho: 0.691, p < .001). For a flare value of 5.75 ph/ms or higher, the sensitivity for predicting angiographic leakage was 70% and the specificity was 94% (AUC: 0.897, p < .001). Flare values that were equal or above 7.6 ph/ms were found to be 100% specific for leakage in the WF-FA. A strong correlation was found between WF-FA leakage and LFP-flare in patients with BU. High LFP-flare levels indicate subclinical posterior segment inflammation in clinically inactive BU.

26 June 2026 in Seminars in Ophthalmology
Verified
Journal Article
Open access
EDEdhem Dogru
Edhem Dogru
MCMatheus Pedrotti Chavez
Matheus Pedrotti Chavez
OTOtávio Toth
Otávio Toth
MSMirella Serafini
Mirella Serafini
MGMelis Kabaalioglu Guner
Melis Kabaalioglu Guner
The comparative efficacy and safety of ranibizumab Port Delivery System (PDS) vs monthly intravitreal ranibizumab in Vascular Endothelial Growth Factor (VEGF)-driven macular diseases remains uncertain. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing PDS vs monthly ranibizumab in neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME). PubMed, Embase, and Cochrane were searched for randomized controlled trials enrolling adults with neovascular age-related macular degeneration or diabetic macular edema treated with the ranibizumab Port Delivery System (100 mg/mL) versus monthly intravitreal ranibizumab 0.5 mg. This systematic review and meta-analysis was conducted according to a predefined PICOTT framework. Continuous and binary outcomes were pooled with mean differences (MDs) and risk ratios (RRs) with a 95% confidence interval (CI), respectively, with a random-effects model. Statistical analyses were performed using RevMan. Three trials were included, with a total of 1,149 eyes of which 688 (60%) received PDS and 461 (40%) received monthly ranibizumab. No significant differences were observed in BCVA (nAMD: MD - 0.69 letters; 95% CI - 2.52 to 1.14; p = .46; DME: MD 0.20; 95% CI - 1.20 to 1.60; p = .78) or CRT (nAMD: MD 26.67 µm; 95% CI - 16.55 to 69.88; p = .23; DME: MD - 3.80; 95% CI - 17.20 to 9.60; p = .58). Incidence of ocular AEs was significantly higher with PDS (RR 1.80; 95% CI 1.49-2.17; p < .00001; I2=74%). Among specific complications, conjunctival bleb or filtering bleb leak (RR 15.29; 95% CI 2.31-101.35; p = .005), conjunctival erosion (RR 8.87; 95% CI 1.66-47.35; p = .01), vitreous hemorrhage (RR 3.61; 95% CI 1.24-10.49; p = .02), hyphema (RR 5.77; 95% CI 1.03-32.20; p = .05), and conjunctival retraction (RR 5.78; 95% CI 1.04-32.29; p = .05) occurred significantly more often with PDS. Systemic AEs were comparable between treatment arms (RR 1.00; 95% CI 0.89-1.13; p = .98). In this systematic review and meta-analysis of three randomized controlled trials, PDS was associated with visual and anatomical results comparable to monthly ranibizumab in patients with nAMD. Evidence in DME was limited to a single trial, and conclusions in this population should be considered exploratory. PDS was associated with a higher incidence of procedure- and device-related ocular complications.

17 September 2025 in Canadian Journal of Ophthalmology
Verified
Journal Article
Closed access
SFSara Fard
Sara Fard
MGMelis Kabaalioglu Guner
Melis Kabaalioglu Guner
WWWei Wang
Wei Wang

28 January 2023 in Canadian Journal of Ophthalmology
Verified
Journal Article
Closed access
MGMelis Kabaalioglu Guner
Melis Kabaalioglu Guner
KFKevin T. Ferenchak
Kevin T. Ferenchak
DSDiva R. Salomao
Diva R. Salomao
LDLauren A. Dalvin
Lauren A. Dalvin

1 March 2026 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
Caroline G. PloegerCaroline G. Ploeger
Caroline G. Ploeger
CVCarolina Carvalho Soares Valentim
Carolina Carvalho Soares Valentim
MGMehmet Eren Guner
Mehmet Eren Guner
MGMelis Kabaalioglu Guner
Melis Kabaalioglu Guner
Purpose: To review and compare the efficacy and safety of adult and pediatric biologic biosimilar use for the treatment of noninfectious uveitis (NIU). Methods: A review of the literature from inception to December 2025 was conducted using Pubmed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science to identify studies that included data or discussion on the use of biosimilar biologic agents for adult and/or pediatric NIU. Articles related to these topics were included and discussed within this review. Results: Most studies examining biosimilar use in adult and pediatric noninfectious uveitis have evaluated the efficacy and safety of anti-tumor necrosis factor alpha (anti-TNF-α) agents, primarily adalimumab and infliximab biosimilars. Identified studies in both adults and children largely consisted of two designs: those comparing reference biologics with biosimilars and switch studies assessing outcomes following conversion to biosimilar therapy. Golimumab, certolizumab pegol, tocilizumab, sarilumab, and rituximab reference biologic studies offer promising results for treatment of NIU, but clinical trials evaluating biosimilar biologics lack in the literature. Compared with adult populations, pediatric cohorts treated with biosimilars for NIU are underrepresented in the literature. Conclusion: Current evidence suggests that adalimumab and infliximab biosimilars are effective and safe in comparison to reference biologics for treatment of NIU in the adult and pediatric populations. Expanded investigation in pediatric cohorts, including prospective clinical trials and inclusion of other biosimilar biologic agents are needed to address current gaps in evidence and to inform clinical decision-making.